Marshall Wace
LRMR icon

Marshall Wace’s Larimar Therapeutics LRMR Stock Holding History

Marshall Wace’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.14M Buy
2,012,458
+1,078,994
+116% +$4.28M ﹤0.01% 1267
2026
Q1 		$4.2M Buy
+933,464
New +$3.73M ﹤0.01% 1383
2025
Q1 		– Sell
-110,304
Closed -$427K – 2892
2024
Q4 		$427K Buy
110,304
+37,810
+52% +$250K ﹤0.01% 2104
2024
Q3 		$475K Sell
72,494
-22,720
-24% -$183K ﹤0.01% 1937
2024
Q2 		$690K Sell
95,214
-4,574
-5% -$35K ﹤0.01% 1833
2024
Q1 		$757K Buy
+99,788
New +$778K ﹤0.01% 1764
2023
Q2 		– Sell
-58,908
Closed -$267K – 2746
2023
Q1 		$267K Buy
+58,908
New +$308K ﹤0.01% 2333
2022
Q4 		– Sell
-38,710
Closed -$124K – 3203
2022
Q3 		$124K Buy
+38,710
New +$97K ﹤0.01% 3160
2022
Q1 		– Sell
-11,392
Closed -$124K – 3722
2021
Q4 		$124K Sell
11,392
-15,195
-57% -$169K ﹤0.01% 3328
2021
Q3 		$306K Buy
26,587
+2,093
+9% +$25.1K ﹤0.01% 2639
2021
Q2 		$240K Sell
24,494
-29,620
-55% -$335K ﹤0.01% 2398
2021
Q1 		$790K Buy
+54,114
New +$983K ﹤0.01% 1770
2015
Q2 		– Sell
-2,198
Closed -$1.04M – 977
2015
Q1 		$1.04M Buy
+2,198
New +$1.04M 0.01% 568
2014
Q4 		– Sell
-7,062
Closed -$1.67M – 889
2014
Q3 		$1.67M Buy
+7,062
New +$1.6M 0.02% 476

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace's LRMR Position: Q2 2026 in Review

Marshall Wace increased its Larimar Therapeutics (LRMR) stake by 116% in Q2 2026, buying an estimated $4.28M and bringing the position to 2,012,458 shares worth $6.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1267.

Marshall Wace first reported a position in LRMR in Q3 2014 and has held it in 14 quarters since. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Marshall Wace held 2,012,458 shares of Larimar Therapeutics worth $6.14M as of Q2 2026.
  • Marshall Wace bought 1,078,994 Larimar Therapeutics shares in Q2 2026, an estimated $4.28M.
  • Larimar Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1267 holding.
  • Marshall Wace first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 14 quarters since.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.